 "Pfizer's Paxlovid")
Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S.public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.
More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. "For those people who really aren't at risk ... I would recommend that they not take it." Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
